Feasibility Study

AFRA Biotech

A center for research, development and production of biotechnology products, focused on the markets of Iran, Central Asia and the Middle East.

Project owner
AFRA Holding
Executing company
AFRA Biotech
Proposed location
Inchebron Free Zone
01 — Executive summary

Research, development & manufacturing

01

Production of biological raw materials

02

Development of recombinant drugs

03

Contract research services (CRO)

04

Contract development & manufacturing (CDMO)

05

Production of diagnostic kits

06

Development of cellular & molecular technologies

02 — Market analysis

Global & regional opportunity

Hundreds of billions → ~$1T

The global biotechnology market has reached hundreds of billions of dollars in recent years and is expected to approach more than a trillion dollars over the next decade, with growth varying by sector (pharmaceutical, agricultural, diagnostic).

7 regional markets

Significant growth potential for biological products and R&D services across the region.

Iran
Kazakhstan
Turkmenistan
Uzbekistan
Azerbaijan
Iraq
Pakistan
03 — Products

Phased product roadmap

I

Phase I

PCR kitsELISA kitsLaboratory enzymesCulture mediaLaboratory raw materials
II

Phase II

Recombinant proteinsResearch antibodiesBiological raw materialsGenetic kits
III

Phase III

Cell therapy (if licensed)Gene therapy (if licensed)Personalized medicineBiobank
04 — Initial investment

Conceptual estimate

Land & building
$40M
Laboratories
$60M
Research equipment
$90M
Production equipment
$110M
Working capital
$50M
Total
~$350M
05 — Human resources

Workforce by specialization

150
Researchers
250
Biotechnology specialists
150
Process engineers
120
Quality control
350
Production
180
Administration & support
Total direct employment: ~1,200 people
06 — Revenue

Baseline scenario

Y1–2

Launch & validation

Focus on launch and validation of technology and processes.

Y3

Sales begin

Start sales and service contracts.

Y5

Scale

Achieve sales of several hundred million dollars, if fully operational with market development and required licenses.

07 — Competitive advantages

Why AFRA Biotech

Location in a Free Zone

Synergy with AFRA Pharma

Development of indigenous technologies

Focus on regional exports

Ability to provide CRO and CDMO services

08 — Risks

Key risk factors

Obtaining specialized licenses

Providing advanced equipment

Attracting specialized human resources

International competition

Currency fluctuations and supply chain

09 — Proposed structure

Organization under AFRA Holding

AFRA Holding → AFRA Biotech
R&D
CRO
CDMO
Diagnostics
Cell Technologies
Genomics
Bioinformatics
Quality Systems
Get in touch

Interested in partnering with AFRA Biotech?

Reach out to the AFRA Holding team to discuss this venture in more detail.